Mitochondrial support Address sleep, oxygenation, movement, oxidative stress and nutrient cofactors
Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
cysteine, glutamic acid and glycine
[6] This binding is thought to induce conformational changes in the receptor, activating associated heterotrimeric G-proteins
Strokes are one of the main causes of adult disability
By activating GLP-1 receptors, these drugs enhance insulin secretion, suppress glucagon release (a hormone that raises blood sugar), and slow gastric emptying, thereby aiding in better blood sugar control